Finance expert

Finance expert

27.11.2012 - Global medical technology specialist Smith & Nephew plc has appointed Julie Brown as Chief Financial Officer (CFO).

The former VP Group Finance and interim CFO of AstraZeneca will formally take up the post in February 2013. Brown brings in 25 years of pharma experience with AstraZeneca, where she held a number of senior financial and management positions

09.07.2012 InDex Pharmaceuticals (Stockholm) has added Stig Løkke Pedersen to its board. The former VP Commercial Operations at H. Lundbeck A/S brings in 25 years of leadership experience and networking in the biotech and pharmaceutical industries.

Pedersen joined Lundbeck in 1992 as CBO, and was selected to join its corporate senior management in 1998. There he served as Executive Vice President from 2003-2011. Pedersen is a partner at Executive Capital A/S and also serves as the Chairman of the Board of Directors at Chemo-metec A/S and Nuevolution A/S.

05.07.2012 Swedish Microbiology specialist Medivir AB has appointed Henric Juserius to head the company's commercial activities. The former Commercial Director (Nordic region) of Actelion Pharmaceuticals will have overall responsibility for the firm's marketing and sales.

His main task will be to prepare the commercial launch of Medivir's Phase III product TMC435, which is being co-developed with Janssen Pharma-ceuticals for hepatitis C. 

20.06.2012 Andrew Bulpin took over Merck-Millipore‘s Process Solutions Business Unit. The chemist – who previously served as Head of Global Pharmaceutical Chemicals Solutions Sales – succeeds the retired Jean-Paul Mangeolle.

Bulpin joined Millipore in 2006 as a Vice President for the firm's Upstream Processing Business Unit. In January 2012, he assumed leadership of the company's Services and Solutions Business Department. Bulpin was appointed to his current position following the company's acquisition by Merck. 

04.06.2012 German Antisense Pharma has looked abroad for fresh inspiration in its management board. At the beginning of May, the Regensburg-based company appointed Dr Philippe Calais as its new Chief Executive Officer.

The Frenchman brings in more than twenty years of international experience in executive positions in both biotech and pharmaceutical firms. Calais successfully guided the development of several drugs through clinical development and commercialisation in his former positions at F. Hoffmann La-Roche and ICI Pharmaceuticals. At Antisense Pharma, he will be responsible for commercialisation of the biopharmaceutical company's lead drug candidate Trabedersen (AP 12009). The antisense drug, which blocks the Transforming GrowthFactor beta 2 (TGF-b2) from being expressed, is currently in Phase III development against glioma, as well as in Phase I/II development for pancreatic cancer and maglignant melanoma. Calais steps in for interim CEO Hubert Heinrichs, who had led the business on an interim basis since July of last year.

07.06.2012 Creabilis SA has appointed Simon Russell as its new Chief Business Officer.

He joins the dermatology, inflammation and pain specialist from Novartis Pharma AG, where he played a number of global strategic marketing roles. Russell moved to Novartis from AstraZeneca, where he worked as Global Brand Strategy Director Biologics. He began his industry career at ICI Pharmaceuticals.

11.06.2012 Cancer nanodelivery firm Nanobiotix has appointed Dr. Bernd Muehlenweg as a member of its Executive Board.

He joined the firm in 2011 as Head of Business Development. Previously, Muehlenweg worked for Wilex AG (Munich) as Director of Business Development, where he played a key role for the company in licencing and commercialisation agreements.

29.05.2012 Alan Schafer is to head British biomarker specialist Population Genetics Technologies Ltd.

The firm's new CEO has a track record in research, Big Pharma management and building new businesses. The former Wellcome Trust’s Director of Science Funding is currently an Adjunct Professor of Innovation at the Imperial College London. He has also served as Global Vice-President of Technology Development at GlaxoSmithKline, and co-founded the functional genomics firm Hexagen.

30.05.2012 EuropaBio has named Miriam Gargesi as its new Director of Healthcare Biotechnology.

She arrives from the Brussels-based EDMA (European Diagnostics Manufacturers Association) where she was the Director for Public Affairs and Communications. Gargesi worked previously as a consultant for Hill & Knowlton and for Kreab
Gavin Anderson. She brings the EDMA extensive knowledge of policymaking gained serving in the Italian Parliament and at the House of Commons in London. Gargesi takes over from Ludovic Lacaine, who had led the division since 2009.

21.05.2012 British Bicycle Therapeutics plc (Cambridge) named Rolf Günther as its new Chief Executive Officer in April. Under the former CEO and COO of Affimed, Bicycle will offer drug discovery partners its proprietary bicyclic peptide technology, which combines the benefits of small molecules with the selectivity of biopharmaceuticals.

The technology platform allows affinity selection of peptides displayed on the surfaces of phages that are linked to an organic scaffold. Günther has more than 21 years of pharmaceutical industry experience, with an extensive background in drug development, biologics and speciality pharmaceuticals. At Affimed, he successfully developed the antibody specialist’s clinical product portfolio in oncology. Günther will continue to be engaged as COO at Affimed in a part-time position until August. He has also held the position of VP and General Manager of the Critical Care business unit of Aventis Behring, which he joined in 1996, and has been responsible for successful drug approvals in both the US and Europe. 

15.05.2012 Tomas Salmonson, the vice-chair of the EMA's Committee for Medicinal Products for Human Use (CHMP), has transiently taken over the tasks of Eric Abadie, who stepped down as CHMP head at the beginning of April.

 After Abadie lost his paid job at the French regulatory agency (Afssaps) because of restructuring, the CHMP was not able to make up his salary.

Vorherige Seite5/6Nächste Seite


Current issue

All issues

Product of the week


Stock list

All quotes


  • RENEURON (UK)2.88 GBP4.73%
  • SUMMIT (UK)4.03 GBP3.87%


  • VITA 34 (D)4.14 EUR-7.17%
  • ADOCIA (F)53.20 EUR-5.67%


  • DIAMYD MEDICAL -B- (S)6.90 SEK59.7%
  • KARO BIO (S)42.00 SEK36.4%


  • BIONOR PHARMA (N)0.44 NOK-25.4%
  • MOLOGEN (D)1.78 EUR-22.6%
  • WILEX (D)1.47 EUR-15.0%


  • NICOX (F)10.07 EUR430.0%
  • SAREUM HOLDINGS (UK)0.76 GBP245.5%
  • GENMAB (DK)1094.00 DKK79.3%


  • BB BIOTECH (D)44.29 EUR-83.5%
  • EVOCUTIS (UK)0.04 GBP-80.0%
  • CIRCASSIA LIMITED (L)92.00 GBP-72.0%

No liability assumed, Date: 26.08.2016


All Events